Vetio
Vetio is a privately held veterinary pharmaceutical CRO/CDMO founded in 2001 in St Louis, United States, specializing in complex drug product formulation and contract manufacturing for animal health companies. It serves veterinary pharmaceutical and biologics firms with formulation, manufacturing, and regulatory support services.
- Company typePrivate
- Founded2001
- HeadquartersSt Louis, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Vetio does
Vetio is a privately held veterinary pharmaceutical contract research and manufacturing organization (CRO/CDMO) founded in 2001 and headquartered in St Louis, United States. The company specializes in complex drug product formulation for animal health applications, serving veterinary pharmaceutical companies that require outsourced development, manufacturing, and regulatory support capabilities. Its positioning addresses a specialized niche within the broader pharmaceutical CDMO market—one focused on animal health products rather than human pharmaceuticals.
The company's service offering spans the full veterinary pharmaceutical product lifecycle, including preclinical and clinical research, formulation development, manufacturing, and regulatory support, based on the stated value proposition of being a partner for the manufacturing of veterinary pharmaceutical products. Vetio operates as a B2B services provider with a vertical segmentation approach, targeting veterinary pharmaceutical and biologics companies as its primary customer segment. The company maintains 101-250 employees, consistent with a mid-sized specialty CDMO.
The business model is project- and contract-based, typical of CDMO engagements, with revenue derived from formulation development fees, manufacturing contracts, and ongoing supply agreements. The company's go-to-market is relationship-driven within the animal health industry, leveraging two decades of accumulated formulation expertise. John Kane serves as Chief Executive Officer. The most recent disclosed capital event was a 2015 funding round from NorthStar Capital. The company has operated continuously for over 23 years, suggesting an established but not rapidly scaling market position within the veterinary pharmaceutical services sector.
Vetio firmographics
Firmographics- Name
- Vetio
- Website
- https://vetio.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Vetio is a privately held veterinary pharmaceutical CRO/CDMO founded in 2001 in St Louis, United States, specializing in complex drug product formulation and contract manufacturing for animal health companies. It serves veterinary pharmaceutical and biologics firms with formulation, manufacturing, and regulatory support services.
- Ownership category
- akta.pro rank
Vetio industry classification
Industry- Product category
- Veterinary Contract Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Veterinary Regenerative Medicine Manufacturing (GMP/CDMO, Cell Processing) (HLAMANAI)
- akta.pro secondary industry
- Compounding Pharmacies (Veterinary) (HLAMAIAD)
Keywords
Where Vetio is headquartered
LocationHeadquarters
- HQ city
- St Louis
- HQ country
- United States
- HQ region
- North America
Markets served
Vetio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Vetio product offering
Product offeringCore offering
Vetio specializes in complex drug product formulation and acts as a contract research and manufacturing partner for veterinary pharmaceutical products. The company delivers preclinical and clinical research, manufacturing, and regulatory support services for animal health products and biologics.
Product overview
No product information available. The source webpage (vetio.com) returned only a loading/verification page ("One moment, please...") without providing product, service, or company overview content.
Differentiator
Problem solved
Functional benefit
Products and services
- Veterinary Pharmaceutical Contract Manufacturing and Research Services End-to-end contract development, formulation, and manufacturing services for veterinary pharmaceuticals and biologics, including complex drug product formulation, preclinical/clinical research, and regulatory support, delivered to animal health companies.
Companies that use Vetio
Customer profileSegments1 record
Ideal customer profiles1 record
Vetio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Vetio partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
Vetio competitors and assessment
Company assessmentBroad incumbents
- Elanco Animal Health: Major animal health pharmaceutical company with internal manufacturing. Comparable as a leading buyer of veterinary CDMO services and as a benchmark for scale in the animal health value chain.
- CordenPharma: CDMOs providing API and drug product manufacturing across therapeutic areas including animal health. Comparable as a contract manufacturer with veterinary exposure and complex formulation expertise.
- Catalent: Major global CDMO with formulation, softgel, and biologic capabilities that also serve animal health customers. Comparable as a broad incumbent whose portfolio overlaps with Vetio's formulation focus.
- PCI Pharma Services: Large global CDMO providing drug development and manufacturing services including for animal health. Comparable as a much larger incumbent offering overlapping veterinary contract manufacturing.
- Eurofins CDMO: Contract development and manufacturing services within Eurofins' broader testing/life sciences platform, including support for animal health sponsors. Comparable as a CDMO serving veterinary pharmaceutical customers.
- Zoetis: World's largest animal health company, headquartered in the same St Louis cluster as Vetio. Comparable as both a potential CDMO customer and a benchmark for the veterinary pharma market Vetio serves.
Direct peers
- Huvepharma: Animal health and nutrition company with manufacturing and product development capabilities. Comparable as a mid-sized animal health player that both produces and sources CDMO capacity.
- Pillar5 Pharma: Specialty CDMO focused on sterile and non-sterile drug product manufacturing for animal health and human health clients. Comparable as a mid-sized CDMO serving veterinary pharma customers.
- Vetoquinol: Independent veterinary pharmaceutical company that both develops its own products and partners with manufacturers. Comparable as a customer-type and adjacent specialty animal health pharma peer.
- Kindeva Drug Delivery: Global CDMO with a dedicated animal health manufacturing franchise. Highly comparable as a contract manufacturer serving veterinary pharmaceutical sponsors with complex formulation and fill-finish capabilities.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat4 records
Key risks4 records
Key highlights5 records
Customer concentration
Vetio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vetio leadership team
Management profileNumber of profiles
Profiles1 record
Vetio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vetio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vetio
What does Vetio do?
Vetio specializes in complex drug product formulation and acts as a contract research and manufacturing partner for veterinary pharmaceutical products. The company delivers preclinical and clinical research, manufacturing, and regulatory support services for animal health products and biologics.
Is Vetio a public or private company?
Vetio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Vetio founded?
Vetio was founded in 2001. It employs 101 to 250 people.
Where is Vetio based?
Vetio is headquartered in St Louis, United States, in the North America region.
Who are Vetio's main competitors?
Broad incumbents on record are Elanco Animal Health, CordenPharma, Catalent, PCI Pharma Services, Eurofins CDMO and Zoetis. Direct peers are Huvepharma, Pillar5 Pharma, Vetoquinol and Kindeva Drug Delivery.
Does Vetio have an API?
No public API is recorded for Vetio.
What industry is Vetio in?
Vetio's product category is Veterinary Contract Manufacturing. Its primary akta.pro industry code is HLAMANAI, Veterinary Regenerative Medicine Manufacturing (GMP/CDMO, Cell Processing), with a secondary code of HLAMAIAD, Compounding Pharmacies (Veterinary). Its NAICS code is 325412 and its SIC code is 2834.